Cantor Fitzgerald Comments on AVITA Medical FY2026 Earnings

AVITA Medical, Inc. (NASDAQ:RCELFree Report) – Research analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for AVITA Medical in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn forecasts that the company will post earnings per share of ($0.23) for the year. The consensus estimate for AVITA Medical’s current full-year earnings is ($0.95) per share.

AVITA Medical (NASDAQ:RCELGet Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.14). AVITA Medical had a negative return on equity of 337.91% and a negative net margin of 96.26%. The business had revenue of $18.51 million for the quarter, compared to analysts’ expectations of $33.15 million.

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $19.00 price objective on shares of AVITA Medical in a report on Friday, June 6th.

Read Our Latest Report on RCEL

AVITA Medical Stock Up 1.2%

RCEL opened at $6.06 on Wednesday. AVITA Medical has a fifty-two week low of $5.46 and a fifty-two week high of $14.16. The company has a debt-to-equity ratio of 9.39, a quick ratio of 2.47 and a current ratio of 2.83. The company has a fifty day moving average of $7.78 and a two-hundred day moving average of $9.42. The stock has a market capitalization of $160.20 million, a price-to-earnings ratio of -2.54 and a beta of 1.55.

Institutional Trading of AVITA Medical

A number of institutional investors and hedge funds have recently modified their holdings of RCEL. AQR Capital Management LLC purchased a new stake in shares of AVITA Medical during the first quarter worth about $799,000. Wellington Management Group LLP acquired a new position in AVITA Medical during the first quarter worth about $669,000. Nuveen LLC acquired a new position in AVITA Medical during the first quarter worth about $584,000. Evernest Financial Advisors LLC acquired a new position in AVITA Medical during the first quarter worth about $411,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in AVITA Medical during the first quarter worth about $374,000. Hedge funds and other institutional investors own 27.66% of the company’s stock.

AVITA Medical Company Profile

(Get Free Report)

AVITA Medical, Inc, together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions.

Featured Stories

Receive News & Ratings for AVITA Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVITA Medical and related companies with MarketBeat.com's FREE daily email newsletter.